Organogenesis Holdings Inc. reported significant financial growth in its fiscal year ending December 31, 2025, with net product revenue reaching $563.0 million, a 17% increase from $482.0 million in 2024. The company also achieved a net income of $37.0 million, compared to a net income of $0.9 million in the previous year. This improvement in profitability was attributed to the successful introduction of new licensed products and increased sales in both the Advanced Wound Care and Surgical & Sports Medicine segments. The Advanced Wound Care segment alone generated $531.2 million in revenue, marking a 17% increase from the prior year, while the Surgical & Sports Medicine segment saw a 12% increase, totaling $31.8 million.
The company experienced a notable rise in operating expenses, which totaled $519.5 million, up from $483.3 million in 2024. This increase was primarily driven by higher selling, general, and administrative expenses, which rose to $326.2 million, reflecting increased commissions and headcount-related costs. Additionally, the company recorded a write-down of $11.2 million related to an asset held for sale, contributing to the overall increase in expenses. Despite these rising costs, the company’s gross profit increased to $425.5 million, a 16% rise from the previous year, indicating improved operational efficiency.
Strategically, Organogenesis has made significant investments in its manufacturing capabilities, including a new biomanufacturing facility in Smithfield, Rhode Island, which is expected to enhance production efficiency and reduce costs. The company plans to resume sales of its Dermagraft product by the end of 2027, following a suspension of manufacturing and distribution in 2021. Furthermore, the company is in the process of submitting a rolling Biologics License Application (BLA) for its ReNu product, aimed at managing symptoms associated with knee osteoarthritis, with completion expected in the first half of 2026.
Operationally, Organogenesis reported a total employee headcount of approximately 854 as of December 31, 2025, reflecting its commitment to expanding its workforce to support growth initiatives. The company also noted a significant increase in accounts receivable, which rose to $233.5 million, indicating strong sales performance but also highlighting potential cash flow challenges. The company’s liquidity position remains solid, with $93.7 million in cash and cash equivalents, alongside a working capital of $259.6 million, which is expected to support ongoing operations and strategic initiatives over the next year.
Looking ahead, Organogenesis faces challenges related to changes in Medicare reimbursement policies, which could impact product utilization and revenue. The company is adapting to these changes by prioritizing certain products and continuing to seek expanded payer coverage. Overall, while the company has demonstrated strong financial performance and strategic growth, it must navigate regulatory changes and market dynamics to sustain its momentum in the regenerative medicine sector.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. specializes in regenerative medicine and tissue-based products for advanced wound care, surgical, and sports medicine markets. Its core offerings include skin substitutes, placental allografts, and collagen biomaterials designed to promote healing of chronic and acute wounds. Serving hospitals, clinics, and surgical centers, the company leverages proprietary technologies, FDA-approved biologics, and a broad product pipeline to address growing healthcare needs driven by aging populations and chronic diseases.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.